Trials / NCT05194124

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

✓ Completed Phase 3 Drug / neuroprotection

Sponsor

Rhythm Pharmaceuticals, Inc.

Treatment

Setmelanotide 2 mg; Setmelanotide 2.5 mg; Setmelanotide 3 mg; Setmelanotide 20 mg; Setmelanotide 25 mg; Setmelanotide 30 mg

Gene

Not stated

Conditions

Bardet-Biedl Syndrome, POMC Deficiency

Ages

6 Years to no upper limit

Enrollment

19 participants

Started

2021-12-21

Main results expected

2023-10-19

Results posted

Yes

Record last updated

2024-11-26

What the study is testing

Where it runs

Open on ClinicalTrials.gov for contacts and eligibility